This text is a result of machine translation.
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Auto Shanghai 2025 - Nullmax Showcases Full-Stack Automated Driving Solutions
On April 23rd, the biennial Shanghai International Automobile Industry Exhibition kicked off grandly. Nullmax, an AI technology company specializing in AD/ADAS solutions for all scenarios, presented its self-developed full-stack MaxDrive solutions. These solutions range from active safety features to autonomous driving solution for urban scenario based on end-to-end technical architecture, catering to the diverse needs of different vehicle models and markets.
Apr 25, 2025 11:24 PM
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
SAIC MAXUS Partners with Huawei Qiankun, Multiple Models to be Launched
On April 23, The 21st Shanghai International Automobile Industry Exhibition (hereinafter referred to as "Auto Shanghai 2025") kicked off, where SAIC Commercial Vehicles unveiled a new strategy to lead the industry's transformation and upgrading. As the core carrier of this strategic upgrade, SAIC MAXUS made its appearance with the theme "Youthful Wealth Creation · Better Life," showcasing multiple wealth-creating new models alongside ecosystem partners, including HUAWEI ADS 4
Apr 25, 2025 08:41 PM
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
$30 Million Lost Annually in the West, Yet Chinese Enterprises Pay No Attention
Apr 30, 2025 11:14 AM
Auto Shanghai 2025 - Nullmax Showcases Full-Stack Automated Driving Solutions
Apr 25, 2025 11:24 PM
SAIC MAXUS Partners with Huawei Qiankun, Multiple Models to be Launched
Apr 25, 2025 08:41 PM